Eurofins Announces the Success of Its Tender Offers on Its Existing Hybrid Bonds

·4 min read

LUXEMBOURG, June 28, 2022--(BUSINESS WIRE)--Regulatory News:

Eurofins Scientific (Paris:ERF) (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch, "Eurofins"), a global leader in bioanalytical testing, announces today the results of the tender offers (the "Tender Offers") to repurchase its €300m Deeply Subordinated Fixed to Floating rate bonds (ISIN: XS2051471105) issued on 11 September 2019 with a first call date in August 2022 (the "2022 Hybrid Bonds") and its €300m Deeply Subordinated Fixed to Floating rate bonds (ISIN: XS1224953882) issued on 29 April 2015 with a first call date in April 2023 (the "2023 Hybrid Bonds" and together with the 2022 Hybrid Bonds, the "Existing Hybrid Bonds").

At the Tender Offers’ expiration deadline (27 June 2022, 5pm CET), Eurofins had received valid tenders of € 307,661,000 in aggregate principal amount of the Existing Hybrid Bonds.

Eurofins has decided to accept for purchase of its Existing Hybrid Bonds respectively (all amounts in EUR):

Bonds

Current Outstanding

Bonds Validly Tendered

Bonds Accepted for Purchase

Remaining Outstanding

2022 Hybrid Bonds

300,000,000

190,390,000

190,390,000

109,610,000

2023 Hybrid Bonds

300,000,000

117,271,000

117,271,000

182,729,000

Total

600,000,000

307,661,000

307,661,000

292,339,000

Settlement of the purchase is expected to take place on 30 June 2022 (the "Settlement Date"). Following the Settlement Date, Eurofins intends to redeem in full the remaining 2022 Hybrid Bonds by exercising its call option.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With 58,000 staff across a decentralised and entrepreneurial network of 900 laboratories in 54 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005723/en/

Contacts

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com
www.eurofins.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting